Company
.:[TICKER]
The Gold Anti-Trust Action Committee was organized in the fall of 1998 to expose, oppose, and litigate against collusion to control the price and supply of gold and related financial instruments. The committee arose from essays by Bill Murphy, a financial commentator on the Internet (LeMetropoleCafe.com), and by Chris Powell, a newspaper editor in Connecticut. Murphy's essays reported evidence of collusion among financial institutions to suppress the price of gold. Powell, whose newspaper had been involved in antitrust litigation, replied with an essay proposing that gold mining and investor interests should act on Murphy's essays by bringing antitrust lawsuits against financial institutions involved in the collusion against gold.
170 stories · page 3 of 9
Emyria’s Phase 1 clinical trial will directly compare the bioavailability of EMD-RX5’s proprietary formulation to the only successfully registered and reimbursed CBD oil in the global market to date, Epidyolex,” says MD.
It has also received approvals to upgrade its existing facility and scale-up Striate+™ manufacturing capacity to more than 100,000 units per year.
The company is focused on regenerating mobility for patients by developing innovative products for the repair of a variety of bone and soft tissue injuries.
“We are currently working with Professor Iain McGregor, an expert in characterising the effects of novel psychoactive substances, as well as A/Prof Matt Piggott and Prof Mat Martin-Iverson, to select animal screening and evaluation programs
“This is exciting research that opens up potential for novel treatments addressing significant unmet medical needs and we will explore these development options alongside our nerve repair applications."
“Following our recent successful animal studies — comparing our formulation to Epidyolex — we also believe EMD-RX5 has the potential to become a registered treatment for multiple indications,” says MD.
“Sixty Two Capital has a track record of supporting high growth client companies over the long-term,” says MD.
“Psychedelic-assisted therapy is showing tremendous promise for patients suffering the most debilitating mental health challenges," managing director Dr Michael Winlo said.
Ultimately, the new data supports the breadth of Orthocell’s cornerstone CelGro™ platform, with positive results recorded across nerve, tendon and bone repair studies.
“These animal study results suggest Emyria has developed a novel, high performing and cost-effective CBD capsule that can meet the strict registration requirements for product quality and purity with both the TGA in Australia and the FDA in
The orthopaedic cell therapy company is in its strongest position yet to launch into the lucrative US market, worth an estimated US$4-5 billion.
In addition, the first patent family has been filed, supported by the initial screening data, with further IP generation underway.
The UN’s tourism body has said the tourism sector’s recovery would be “fragile” and “slow”, but the pandemic would cost the global tourism sector $US2 trillion in lost revenue in 2021.
“Emyria is uniquely placed to accelerate treatment development as one of only a few companies operating a network of clinical services, curating proprietary Real-World Evidence and developing novel treatments,” Dr Karen Smith said.
"The near-term rise in inflation is accentuated by higher oil prices, rising transport costs and the impact of supply shortfalls," the RBZA says.
The R&D Tax Incentive is an Australian Government program under which eligible companies can receive cash rebates of up to 43.5% of eligible expenditure on R&D activities.
“We are starting to see more and more Victorians booking a much-deserved international getaway, and as borders open up to international visitors we’re expecting to see them visit Melbourne in large numbers, which will give local tourism and
“Tattarang shares our long-term vision to accelerate the development and registration of medicines that can transform the lives of millions of people around the world living with conditions for which current therapies are either ineffective
“This is an important development milestone for OrthoATI® and the company and I am delighted to have reached this pivotal stage of the study,” says MD.
“We are pleased to be working with global leader Eurofins to screen our first batch of novel MDMA-analogues after successfully completing purity and stability testing at UWA,” says MD.
